Peptidoglycan synthesis involves a multi-step pathway that includes nucleotide precursor formation, lipid carrier assembly, and cross-linking by penicillin-binding proteins. The cell wall must simultaneously grow and maintain strength, requiring coordinated synthesis and degradation (remodeling) of peptidoglycan.
Draw the complete biosynthetic pathway from UDP-NAG/NAM through to cross-linked dimers. Understand how antibiotics like beta-lactams disrupt this process by inhibiting penicillin-binding proteins.
Peptidoglycan synthesis happens only at cell division—in fact, bacteria continuously remodel their walls during growth. The process is highly regulated and vulnerable to antibiotic attack at multiple steps.
From your study of bacterial cell wall architecture, you know that peptidoglycan is the mesh-like polymer that gives bacterial cells their shape and protects them from osmotic lysis. The internal turgor pressure of a bacterium can reach 5–25 atmospheres — comparable to the pressure inside a car tire — so the cell wall must be extraordinarily strong. But here is the engineering challenge: the bacterium must also grow and divide, which means it must continuously expand and remodel this load-bearing structure without ever compromising its integrity. It is like renovating a submarine while it is underwater.
Peptidoglycan synthesis begins in the cytoplasm with the construction of nucleotide sugar precursors. The enzyme MurA attaches a phosphoenolpyruvate group to UDP-N-acetylglucosamine (UDP-NAG), which is then converted to UDP-N-acetylmuramic acid (UDP-NAM). A short peptide chain (typically five amino acids) is then added stepwise to UDP-NAM, creating the muropeptide monomer. This entire precursor is then transferred to a membrane-embedded lipid carrier called undecaprenyl phosphate (C₅₅-P), forming Lipid I. Addition of a second NAG sugar produces Lipid II — the complete peptidoglycan building block, now anchored in the inner membrane and ready for export.
Lipid II is flipped across the inner membrane by a flippase (MurJ), delivering the disaccharide-peptide unit to the periplasmic side. There, transglycosylases polymerize the sugar units into long glycan chains by linking NAM-NAG repeats through β-1,4 glycosidic bonds. Transpeptidases — also known as penicillin-binding proteins (PBPs) — then cross-link the peptide stems of adjacent glycan chains, creating the covalent mesh that gives peptidoglycan its tensile strength. This cross-linking step is the target of beta-lactam antibiotics like penicillin: these drugs mimic the D-Ala-D-Ala terminus of the peptide stem, binding covalently to the transpeptidase active site and permanently inactivating it.
Remodeling is equally important. As the cell grows, autolysins — enzymes like amidases, endopeptidases, and lytic transglycosylases — selectively cleave existing bonds in the peptidoglycan mesh, creating gaps where new material can be inserted. This must be tightly coordinated with new synthesis: too much autolysis without enough new cross-linking, and the cell wall fails catastrophically, causing lysis. Too little autolysis, and the cell cannot expand or divide. Bacteria regulate this balance through a combination of spatial targeting (directing synthesis and hydrolysis to specific zones, such as the division septum), regulatory proteins, and mechanical sensing of wall stress. This coordination is precisely why antibiotics that target peptidoglycan synthesis are so effective — they disrupt a process where timing and balance are everything.